Fortress Biotech, Inc. Selling, General and Administrative Expense
Fortress Biotech, Inc. (FBIO) reported Selling, General and Administrative Expense of $20.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Fortress Biotech, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $20.81M, a 46.31% decline year-over-year.
- Fortress Biotech, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $15.89M, a 38.07% decline year-over-year.
- Fortress Biotech, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $14.73M, a 45.17% decline year-over-year.
- Fortress Biotech, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $17.41M, a 20.82% decline year-over-year.
- Fortress Biotech, Inc. selling, general and administrative expense for fiscal 2025 was $96.40M, a 9.88% increase from fiscal 2024.
- Fortress Biotech, Inc. selling, general and administrative expense for fiscal 2024 was $87.73M, a 3.57% decline from fiscal 2023.
- Fortress Biotech, Inc. selling, general and administrative expense for fiscal 2023 was $90.98M, a 19.95% decline from fiscal 2022.
- Fortress Biotech, Inc. selling, general and administrative expense for fiscal 2022 was $113.66M, a 30.88% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $20.81M 10-Q · filed 2026-08-13 | $36.70M 10-Q · filed 2026-08-13 | $51.43M derived: sum of 3 quarters · filed 2026-08-13 | $68.84M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $15.89M 10-Q · filed 2026-05-14 | $30.62M derived: sum of 2 quarters · filed 2026-05-14 | $48.04M derived: sum of 3 quarters · filed 2026-05-14 | $86.80M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $14.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $32.15M derived: sum of 2 quarters · filed 2026-03-31 | $70.90M derived: sum of 3 quarters · filed 2026-08-13 | $96.40M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $17.41M 10-Q · filed 2025-11-14 | $56.17M derived: sum of 2 quarters · filed 2026-08-13 | $81.67M 10-Q · filed 2025-11-14 | $108.70M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $38.76M 10-Q · filed 2026-08-13 | $64.42M 10-Q · filed 2026-08-13 | $91.28M derived: sum of 3 quarters · filed 2026-08-13 | $113.28M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $25.66M 10-Q · filed 2026-05-14 | $52.53M derived: sum of 2 quarters · filed 2026-05-14 | $74.52M derived: sum of 3 quarters · filed 2026-05-14 | $95.34M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $26.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $48.86M derived: sum of 2 quarters · filed 2026-03-31 | $69.68M derived: sum of 3 quarters · filed 2026-03-31 | $87.73M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $21.99M 10-Q · filed 2025-11-14 | $42.82M derived: sum of 2 quarters · filed 2025-11-14 | $60.87M 10-Q · filed 2025-11-14 | $80.23M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $20.82M 10-Q · filed 2025-08-14 | $38.78M 10-Q · filed 2025-08-14 | $58.23M derived: sum of 3 quarters · filed 2025-08-14 | $79.97M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $17.94M 10-Q · filed 2025-05-15 | $37.41M derived: sum of 2 quarters · filed 2025-05-15 | $59.14M derived: sum of 3 quarters · filed 2025-05-15 | $83.58M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $19.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $41.20M derived: sum of 2 quarters · filed 2025-03-31 | $65.64M derived: sum of 3 quarters · filed 2025-03-31 | $90.98M 10-K · filed 2025-03-31 | $94.12M 10-K · filed 2024-03-28 |
| 2023-09-30 | $21.73M 10-Q · filed 2024-11-14 | $46.17M derived: sum of 2 quarters · filed 2024-11-14 | $71.51M 10-Q · filed 2024-11-14 | $99.71M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $24.44M 10-Q · filed 2024-08-13 | $49.78M 10-Q · filed 2024-08-13 | $77.98M derived: sum of 3 quarters · filed 2024-08-13 | $108.12M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $25.34M 10-Q · filed 2024-05-15 | $53.54M derived: sum of 2 quarters · filed 2024-05-15 | $83.68M derived: sum of 3 quarters · filed 2024-05-15 | $112.73M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $28.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $58.34M derived: sum of 2 quarters · filed 2024-03-28 | $87.39M derived: sum of 3 quarters · filed 2024-03-28 | $113.66M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $30.14M 10-Q · filed 2023-11-14 | $59.19M derived: sum of 2 quarters · filed 2023-11-14 | $85.46M 10-Q · filed 2023-11-14 | $113.16M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $29.05M 10-Q · filed 2023-08-14 | $55.32M 10-Q · filed 2023-08-14 | $83.02M derived: sum of 3 quarters · filed 2023-08-14 | $105.24M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $26.27M 10-Q · filed 2023-05-15 | $53.97M derived: sum of 2 quarters · filed 2023-05-15 | $76.19M derived: sum of 3 quarters · filed 2023-05-15 | $95.57M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $27.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $49.92M derived: sum of 2 quarters · filed 2023-03-31 | $69.30M derived: sum of 3 quarters · filed 2023-03-31 | $86.84M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $22.22M 10-Q · filed 2022-11-14 | $41.60M derived: sum of 2 quarters · filed 2022-11-14 | $59.15M 10-Q · filed 2022-11-14 | $74.95M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $19.38M 10-Q · filed 2022-08-11 | $36.92M 10-Q · filed 2022-08-11 | $52.73M derived: sum of 3 quarters · filed 2022-08-11 | $68.11M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $17.54M 10-Q · filed 2022-05-12 | $33.35M derived: sum of 2 quarters · filed 2022-05-12 | $48.73M derived: sum of 3 quarters · filed 2022-05-12 | $63.19M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $15.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $31.19M derived: sum of 2 quarters · filed 2022-03-28 | $45.65M derived: sum of 3 quarters · filed 2022-03-28 | $61.17M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $15.38M 10-Q · filed 2021-11-15 | $29.84M derived: sum of 2 quarters · filed 2021-11-15 | $45.36M 10-Q · filed 2021-11-15 | $59.69M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $14.46M 10-Q · filed 2021-08-16 | $29.98M 10-Q · filed 2021-08-16 | $44.30M derived: sum of 3 quarters · filed 2021-08-16 | $58.64M derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | $15.52M 10-Q · filed 2021-05-17 | $29.85M derived: sum of 2 quarters · filed 2021-05-17 | $44.19M derived: sum of 3 quarters · filed 2021-05-17 | $57.63M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $14.33M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $28.67M derived: sum of 2 quarters · filed 2021-04-09 | $42.11M derived: sum of 3 quarters · filed 2021-04-09 | $55.59M 10-K/A · filed 2021-04-09 | |
| 2019-09-30 | $14.34M 10-Q · filed 2020-11-09 | $27.78M derived: sum of 2 quarters · filed 2020-11-09 | $41.26M 10-Q · filed 2020-11-09 | $55.84M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $13.44M 10-Q · filed 2020-08-10 | $26.92M 10-Q · filed 2020-08-10 | $41.50M derived: sum of 3 quarters · filed 2020-08-10 | $53.69M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $13.48M 10-Q · filed 2020-05-11 | $28.06M derived: sum of 2 quarters · filed 2020-05-11 | $40.24M derived: sum of 3 quarters · filed 2020-05-11 | ||
| 2018-12-31 | $14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $26.77M derived: sum of 2 quarters · filed 2020-03-16 | $53.37M 10-K · filed 2020-03-16 | ||
| 2018-09-30 | $12.18M 10-Q · filed 2019-11-12 | $38.79M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |